TokenPost·
Genmab Reports Three Phase 3 Wins; Shares Rose 91.5% From Aug. 3 to Nov. 2
Petosemtamab and Rina-S came through acquisitions, while Genmab is developing epcoritamab with AbbVie.
More news
- DecryptBinance Misses Monthly Luna Classic Burn for First Time Since 2023
- TokenPostDeFiChain (DFI) Drops 35.34% in 15 Minutes on Nov. 3
- CryptoPotatoWall Street’s Bear Market Is No Longer So Stealthy
- TokenPostXRP Bollinger Bands Narrow to Tightest Since August, Martinez Says
- TokenPostChina, Oman Sign Five-Year, 30 Billion Yuan Currency Swap
- CoinGapeBitget Expands IPO Prime With Anthropic ANT Offering Ahead of Planned Public Listing